Company: IOBT
Filing Date: 2025-05-23
Form Type: S-3
Source: 0001193125-25-125831
Chunk: 13

Company: IO Biotech, Inc.
Filing Date: 2025-05-23
Form: S-3
Chunk 13
---
 product 
 candidates;                                                                                                 |

| • |     | the rate and degree of market acceptance of Cylembio®,                                                                  
 IO112, IO170 or any other product candidates we may identify and pursue, if approved by the relevant regulatory bodies; |

| • |     | our ability to obtain orphan drug designation, Breakthrough Therapy Designation (BTD), accelerated or other 
 approval for any product candidates we may identify;                                                        |

| • |     | our expectations regarding government and third-party payor coverage and reimbursement; |

| • |     | our ability to manufacture, including through contract manufacturing organizations (CMOs), Cylembio®, IO112, IO170 or any other product candidate in conformity with the Food and Drug Administration’s (FDA’s) requirements and the requirements of other applicable regulatory authorities; |

| • |     | our ability to successfully build a sales force and commercial infrastructure; |

| • |     | our ability to compete with companies currently producing or engaged in the clinical development of treatments 
 for the disease indications that we pursue and treatment modalities that we develop;                           |

| • |     | our reliance on third parties to conduct our clinical trials; |

| • |     | our reliance on third-party CMOs to manufacture and supply our product candidates for us; |

| • |     | our ability to retain and recruit key personnel; |

| • |     | our ability to obtain and maintain intellectual property protection for Cylembio®, IO112, IO170 or any other product candidates we may identify and pursue; |

| • |     | our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability 
 to obtain additional financing;                                                                                  |

| • |     | our expectations regarding the time during which we will be an emerging growth company (EGC) under the Jumpstart 
 Our Business Startups Act (JOBS Act);                                                                            |

| • |     | our financial performance; |

| • |     | the effect of significant public health emergencies or geopolitical events on any of the foregoing or any other 
 aspects of our business operations;                                                                             |

| • |     | the impact of laws and regulations, including legislative developments; and developments and projections relating 
 to our competitors or our industry.                                                                               |

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or